Cart
sales@molnova.com
Fluorogenic Human CMV Protease Substrate
CAS No. 163265-38-1
Fluorogenic Human CMV Protease Substrate( ——— )
Catalog No. M39903 CAS No. 163265-38-1
Dabcyl-RGVVNASSRLA-Edans (Dabcyl-CMV-Edans) is a fluorogenic substrate for human cytomegalovirus (HCMV) protease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFluorogenic Human CMV Protease Substrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionDabcyl-RGVVNASSRLA-Edans (Dabcyl-CMV-Edans) is a fluorogenic substrate for human cytomegalovirus (HCMV) protease.
-
DescriptionDabcyl-RGVVNASSRLA-Edans (Dabcyl-CMV-Edans) is a fluorogenic substrate for human cytomegalovirus (HCMV) protease.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number163265-38-1
-
Formula Weight1628.85
-
Molecular FormulaC73H109N23O18S
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Holskin BP, et al. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Anal Biochem. 1995 May 1;227(1):148-55. ?
molnova catalog
related products
-
Etrolizumab
Etrolizumab (rhuMAb Beta7), a gut-selective anti-β7 integrin monoclonal antibody, targets the β7 subunit of α4β7 and αEβ7 integrins specifically, demonstrating affinity with K i values of 18 nM for Human α4β7 and 1800 pM for Human αEβ7-293.
-
β-Amyloid/A4 Protein...
β-Amyloid/A4 Protein Precursor (APP) (328 - 332)
-
FFAGLDD
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release.
